These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 11150901)

  • 1. Vaccination for malignant melanoma: recent developments.
    Jäger D; Jäger E; Knuth A
    Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the development of vaccines to treat breast cancer.
    Jäger E; Jäger D; Knuth A
    Recent Results Cancer Res; 1998; 152():94-102. PubMed ID: 9928550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease.
    Jäger E; Jäger D; Knuth A
    Cancer Metastasis Rev; 1999; 18(1):143-50. PubMed ID: 10505552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
    Jäger D; Jäger E; Knuth A
    J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy in clinical oncology.
    Knuth A; Jäger D; Jäger E
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S46-51. PubMed ID: 10950148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Vaccination in Clinical Oncology.
    Jäger E; Jäger D; Knuth A
    Onkologie; 2000 Oct; 23(5):410-415. PubMed ID: 11441234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.
    Jäger E; Gnjatic S; Nagata Y; Stockert E; Jäger D; Karbach J; Neumann A; Rieckenberg J; Chen YT; Ritter G; Hoffman E; Arand M; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12198-203. PubMed ID: 11027314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
    Jäger E; Nagata Y; Gnjatic S; Wada H; Stockert E; Karbach J; Dunbar PR; Lee SY; Jungbluth A; Jäger D; Arand M; Ritter G; Cerundolo V; Dupont B; Chen YT; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4760-5. PubMed ID: 10781081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
    Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
    Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.
    Gnjatic S; Jäger E; Chen W; Altorki NK; Matsuo M; Lee SY; Chen Q; Nagata Y; Atanackovic D; Chen YT; Ritter G; Cebon J; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11813-8. PubMed ID: 12186971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
    Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
    J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.